NCT01771705View on ClinicalTrials.gov

NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 2, 2013

Primary Completion Date

August 13, 2016

Study Completion Date

April 17, 2017

Conditions
Kidney Transplantation
Interventions
OTHER

Dose adjust group (NFAT)

If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

University of California, San Francisco

OTHER